Baloxavir, a cap-dependent endonuclease inhibitor, was recently approved for treatment of severe influenza infections. Combining baloxavir with oseltamivir has been proposed to increase the response rate. We report 2 hematopoietic cell transplant recipients with severe influenza infections who were treated with this combination and discuss possible reasons for their different responses.
Combination of Baloxavir and Oseltamivir for Treatment of Severe Influenza Infection in Hematopoietic Cell Transplant Recipients: A Novel Treatment Strategy for a High-risk Population.